For a time, the company looked like a high-upside growth stock. However, that story was put to the test in December, when ...
The Bancorp, Inc. is rated Hold due to valuation concerns despite strong asset quality & recent share price decline. Learn ...
An FDA panel of experts has called for a loosening of regulations and expanding access to testosterone replacement therapy.
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral reboundsActivity shown in ...
The FDA taps J&J drug teclistamab for its National Priority Voucher pilot, enabling expedited review for multiple myeloma treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback